Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter

Market Access Monitor

Service of monitoring key reimbursement and HTA developments for medical devices, in-vitro diagnostic tests, and digital technologies in Europe and globally

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Companion diagnostic tests
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
See all tags

2025 In-Vitro Diagnostic Tests Market Access Playbook Released

Stay ahead of reimbursement authorities and your competitors with our Europe-wide Market Access Calendar for IVD tests, 2025. Inside, you will find every key filing window and reimbursement submission date that can make or break your launch timeline.

Because the major reimbursement milestones repeat on the same cadence year after year, this calendar is designed as an annual reference you can refresh and reuse for every coming season.

We spotlight only the milestones that run on fixed schedules, so you’ll never miss a hard cutoff. Flexible windows are flagged. When authorities publish a range instead of a date, we mark it as “flexible” helping you plan resources without false alarms.

Pin, share, and keep it on hand - your annual shortcut to flawless market access execution.

Request a Pocket Brief and deepen your understanding of key EU reimbursement timelines to ensure smooth market access for IVD tests in 2025 and beyond

Tags
Services of MTRC

The latest related news

11
Aug 2025

Bi-weekly snapshot of market access and HEOR project work at MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of August 11th, we plan to work on 16 projects. Review the complete list of planned activities in this post.
Read more
08
Aug 2025

MTRC has released a White Paper "Evidence Requirements for IVD Tests in NICE HealthTech Evaluations”

MTRC has released a White Paper titled "Evidence Requirements for IVD Tests in NICE HealthTech Evaluations ". This white paper reviews five assessments of IVD diagnostic technologies conducted under NICE’s previous Diagnostics Assessment Programme (DAP) framework. While terminology and processes have evolved with the introduction of the HealthTech Evaluation Program, these case studies remain highly informative. They offer practical insights into NICE’s evidence expectations and common drivers of recommendation decisions, which continue to shape current evaluation approaches.
Read more
28
Jul 2025

Bi-weekly snapshot of market access and HEOR project work at MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of July 28th, we plan to work on 16 projects. Review the complete list of planned activities in this post.
Read more
23
Jul 2025

MTRC has released a White Paper "Clinical evidence requirements for the “Orderly Introduction of Medical Technologies” process in Sweden"

MTRC has released a White Paper titled "Clinical evidence requirements for the “Orderly Introduction of Medical Technologies” process in Sweden". This report provides an opportunity to learn about the evidence requirements of Sweden's Dental and Pharmaceutical Benefits Agency (TLV) and the Medical Technology Product (MTP) Council in relation to the national process of Orderly Introduction of medical technologies. White Paper outlines the key points and recommendations for the MedTech industry informed by three HTA reports with positive recommendations.
Read more
18
Jul 2025

MTRC has released a White Paper "Evidence requirements for AI-based technologies in Europe"

MTRC has released a White Paper titled "Evidence requirements for AI-based technologies in Europe." This Paper reviews evidence requirements for AI-based technologies as identified in five recent European HTA assessments, including urgent-care fracture detection (NICE, UK), hyperacute stroke imaging (NICE, UK), colonoscopic polyp detection (Danish Health Technology Council), and breast cancer screening programs (OSTEBA in Spain and SBU in Sweden).
Read more